New possibility in therapy of diabetes mellitus: co-formulation of insulin degludec and insulin aspart
Authors:
Zbynek Schroner
Authors‘ workplace:
LF UPJŠ a SchronerMED s. r o., Košice
Published in:
Diab Obez 2021; 21(42): 76-79
Category:
Overview
1st Oct 2021 came to clinical practice in Slovak republic new co-formulation of insulin degludec and insulin aspart (IDegAsp). Clinical trial program with IDegAsp has the name BOOST. It was tested in adult and child type 1 diabetics, also in type 2 diabetics. In patients with type 2 diabetes it was given not only to insulin-naive patients, but also in patients inadequately controlled on basal or premix insulin. IDegAsp among all the trials proved good glycemic control, lower insulin dose and risk of hypoglycemia. It is possible to give it flexible, according to which meal is for patient main. In comparison with basal bolus regimen is its advantage flexibility in dose timing and number of daily injections and lower risk of hypoglycemia.
Keywords:
clinical studies – insulin aspart – insulin degludec – co-formulation
Sources
1. Havelund S, Ribel U, Hoeg-Jensen T et al. Investigation of the physico-chemical properties that enable co-formulation of basal insulin degludec with fast-acting insulin aspart. Pharm Res 2015; 32(7): 2250–2258. Dostupné z DOI: <http://dx.doi.org/10.1007/s11095–014–1614-x>.
2. Atkin S, Javed Z, Fulcher G. Insulin degludec and insulin aspart: novel insulins for the management of diabetes mellitus. Ther Adv Chronic Dis 2015; 6(6): 375–388. Dostupné z DOI: <http://dx.doi.org/10.1177/2040622315608646>.
3. Hirsh LB, Franek E, Mersebah H et al. Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal–bolus treatment in people with Type 1 diabetes: 1–year results from a randomized clinical trial (BOOST® T1). Diabet Med 2017; 34(2): 167–173. Dostupné z DOI: <http://dx.doi.org/10.1111/dme.13068>.
4. Fulcher GR, Christiansen JS, Bantwal G et al. [BOOST: Intensify Premix I Investigators]. Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial. Diabetes Care 2014; 37(8): 2084–2090. Dostupné z DOI:<http://dx.doi.org/10.2337/dc13–2908>.
5. Kaneko S, Chow F, Choi DS et al. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: a 26-week, randomised, treat-to-target trial. Diabetes Res Clin Pract 2015; 107(1): 139–147. Dostupné z DOI:<http://dx.doi.org/10.1016/j.diabres.2014.09.026>.
6. Haluzík M, Fulcher G, Fieber TR et al. The co-formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease uration or body mass index: a pooled metaanalysis of phase III studies in patients with type 2 diabetes. Diabetes Obes Metab 2018; 20(7): 1585–1592. Dostupné z DOI:<http://dx.doi.org/10.1111/dom.13261>.
7. Fulcher G, Mehta R, Fita EG et al. Efficacy and safety of IDegAsp versus BIAsp 30, both twice daily, in elderly patients with type 2 diabetes: post hoc analysis of two phase 3 randomized controlled BOOST trials. Diabetes Ther 2019; 10(1): 107–118. Dostupné z DOI:<http://dx.doi.org/10.1007/s13300–018–0531–0>.
8. Ryzodeg (inzulín degludek/ inzulín aspartát). Súhrn charakteristických vlastností lieku. Dostupné z WWW: <https://w w w.ema.europa.eu/en/documents/produc t-information/ryzodeg-epar-product-information_sk.pdf>.
Labels
Diabetology ObesitologyArticle was published in
Diabetes a obezita
2021 Issue 42
Most read in this issue
- New possibility in therapy of diabetes mellitus: co-formulation of insulin degludec and insulin aspart
- Compensation of social consequences of diabetes mellitus
- News in the field of SGLT2 inhibitors
- XXXIst diabetes days with international participation